Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 4901–4950 of 33482
On February 4, 2025, Jason Keyes, Interim Chief Executive Officer, and Marc Landy, Interim Chief Financial Officer, provided notice of their resignations from their positions with the Company effective as of the Announcement Date.
On February 4, 2025, Jason Keyes, Interim Chief Executive Officer, and Marc Landy, Interim Chief Financial Officer, provided notice of their resignations from their positions with the Company effective as of the Announcement Date.
On February 3, 2025, Christopher A. Coughlin, Executive Vice President, President of Industrial Motion, of the Company notified the Company of his intention to retire by the end of December 2025.
On January 31, 2025, William A. Kozy informed the Board of Directors (the "Board") that he will retire as a director, effective on the date of The Cooper Companies, Inc.'s (the "Company's") next Annual Meeting of Stockholders in April 2025 (the "Annual Meeting").
On January 31, 2025, Busy Burr notified the Board of Directors (the “Board”) of Mr. Cooper Group Inc. (the “Company”) that she has decided to resign from the Board effective immediately.
On January 30, 2025, Xometry, Inc. (the “Company”) and Matt Leibel, the Company’s Chief Technology Officer, mutually agreed that Mr. Leibel would separate from his role at the Company effective as of February 5, 2025 (the “Effective Date”).
On February 5, 2025, the Company and Jeff Dossett, the Company’s Chief Revenue Officer, announced that Mr. Dossett intends to retire and will depart the Company effective February 21, 2025.
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
it was determined that each of Mark Rothera, President and Chief Executive Officer, Michael Faerm, Chief Financial Officer, and Darrel P. Cohen M.D., Ph.D., Chief Medical Officer, would cease serving in their respective officer positions as of the Effective Time.
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
Roger Pomerantz, M.D., Flavia Borellini, Ph.D., Thomas E. Darcy, CPA, Ivor Royston, M.D., and Mark Rothera, representing all of the Company's current Board members, each notified the Company of their respective resignations as members of the Board
David Stefko, who was appointed interim Chief Executive Officer of the Company on March 26, 2024, will resign from such position effective February 6, 2025, but remain with the Company for a transition period in a non-executive capacity and will continue to serve as a member of the Board.
R. Kipp deVeer will cease to serve as Chief Executive Officer
On February 3, 2025, Eric Rose, M.D., notified the Company of his resignation from the Board, effective immediately.
Each of Matthew Messinger, Keith Pattiz and Dan Bartok have tendered their resignation from the Board and as a member of any committees of the Board, which resignation will become effective immediately at the Closing Date
Each of Matthew Messinger, Keith Pattiz and Dan Bartok have tendered their resignation from the Board and as a member of any committees of the Board, which resignation will become effective immediately at the Closing Date
Each of Matthew Messinger, Keith Pattiz and Dan Bartok have tendered their resignation from the Board and as a member of any committees of the Board, which resignation will become effective immediately at the Closing Date
Mr. Oliver will continue to serve as the Chairman of the Board of Directors of the Company until July 31, 2025, and will retire from the Board of Directors on that date.
announced that Joakim Weidemanis, 55, will join the Company and succeed George Oliver as the Company’s Chief Executive Officer and principal executive officer.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
Joseph Carleone, Ph.D., Esther Alegria, Ph.D., Richard Hancock, Catherine Mackey, Ph.D., Gregory Sargen and Jeanne Thoma, each of whom was a director of the Company as of immediately prior to the Effective Time, ceased to be a director of the Company and a member of any committee of the Company’s Board of Directors.
the Company also announced the departure of David Wilkinson from his role as President and Chief Executive Officer of the Company, effective as of February 4, 2025.
On February 5, 2025, Dine Brands Global, Inc., a Delaware corporation (the “Corporation”), announced Tony E. Moralejo, President, Applebee’s Business Unit, will be departing his current role with the Corporation, effective as of March 4, 2025.
Brian Millham announced that he will be retiring from the Company. Mr. Millham will step down from his role as the Company’s President and Chief Operating Officer as of the Effective Date
Richard Drexler resigned as a member of the Board of Directors (the “Board”) of Agrify Corporation (the “Company”).
On February 1, 2025, Edward Myers resigned from his positions as Chief Operating Officer and Interim Chief Financial Officer of the Company.
On February 3, 2025, Charles M. Kelley, Senior Vice President, Commercial Natural Gas Pipelines and a named executive officer in our most recent proxy statement, provided notice of his intention to retire effective March 31, 2025.
Jonah Meer and Ido Merfeld resigned as directors of the Company
Jonah Meer and Ido Merfeld resigned as directors of the Company
On January 30, 2025, Christopher Davenport resigned from the Board of Directors and as Chief Executive Officer of both Assignors effective contemporaneous with the execution of the Assignments and effectuation of the Assignments.
On February 1, 2025, Royalty Management Holding Corporation (or the “Company”) was informed by Kirk Taylor, the Company’s Chief Financial Officer, that he will resign from such position effective February 1, 2025.
Calum Hughes resigned as Chief Executive Officer and a Director of the Company.
Timothy J. Martin, Executive Vice President, Chief Global Solutions Officer, notified TransUnion (the “Company”) that he intends to retire from the Company in September 2026
On January 30, 2025, Christina Luconi, Chief People Officer of Rapid7, Inc. (the “ Company ”), notified the Company of her resignation from her position.
On February 4, 2025 , Jamie L. Prah voluntarily resigned as Executive Vice President and Chief Financial Officer of CB Financial Services, Inc. (the “Company”) and its subsidiary bank, Community Bank (the “Bank”).
On February 4, 2025, Mr. Richard D. Moss notified the board of his decision to not stand for re-election at the company's upcoming 2025 annual shareholder meeting.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.